Compare FSLY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | VCEL |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2019 | 1996 |
| Metric | FSLY | VCEL |
|---|---|---|
| Price | $30.11 | $44.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $18.00 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 6.5M | 460.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.19 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $624,018,000.00 | $276,259,000.00 |
| Revenue This Year | $16.39 | $19.40 |
| Revenue Next Year | $10.73 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 14.78 | ★ 16.45 |
| 52 Week Low | $6.84 | $28.95 |
| 52 Week High | $34.82 | $49.32 |
| Indicator | FSLY | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 73.06 | 46.04 |
| Support Level | $23.88 | $32.44 |
| Resistance Level | $33.79 | $49.04 |
| Average True Range (ATR) | 2.12 | 1.56 |
| MACD | 0.74 | -0.39 |
| Stochastic Oscillator | 93.58 | 16.94 |
Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.